Enhertu Approved in the US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors

April 6, 2024 -- AstraZeneca and Daiichi Sankyo ' s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news